Caroline N. Do Wojtas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caroline N. Do Wojtas has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Brett M. Behers
University of South Florida College of Medicine, Tampa, FL, USA
2 shared publications - Manuel A. Rosario
Florida State University Internal Medicine Residency, Sarasota Memorial Hospital, Sarasota, FL
2 shared publications - Alexander C. Deevers
Department of Clinical Research, University of Florida, Gainesville, FL 32603, USA
1 shared publication - Anthony Thompson
Florida State University College of Medicine Tallahassee Florida USA
1 shared publication Benjamin J. Behers
Florida State University Internal Medicine Residency, Sarasota Memorial Hospital, Sarasota, FL
1 shared publication- Benjamin J. Behers
Florida State University Internal Medicine Residency at Sarasota Memorial Hospital, Sarasota, FL 34239, USA
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 11 April 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (15) , e42135
Assessing the quality and readability of patient education materials on chemotherapy cardiotoxicity from artificial intelligence chatbots: An observational cross-sectional study
Artificial intelligence (AI) and the introduction of Large Language Model (LLM) chatbots have become a common source of patient inquiry in healthcare. The quality and readability of AI-generated patient education materials (PEM) is the subject of many studies across multiple medical topics. Most demonstrate poor readability and acceptable quality. However, an area yet to be investigated is chemotherapy-induced cardiotoxicity. This study seeks to assess the quality and readability of chatbot created PEM relative to chemotherapy-induced cardiotoxicity. We conducted an observational cross-sectional study in August 2024 by asking 10 questions to 4 chatbots: ChatGPT, Microsoft Copilot (Copilot), Google Gemini (Gemini), and Meta AI (Meta). The generated material was assessed for readability using 7 tools: Flesch Reading Ease Score (FRES), Flesch-Kincaid Grade Level (FKGL), Gunning Fog Index (GFI), Coleman-Liau Index (CLI), Simple Measure of Gobbledygook (SMOG) Index, Automated Readability Index (ARI), and FORCAST Grade Level. Quality was assessed using modified versions of 2 validated tools: the Patient Education Materials Assessment Tool (PEMAT), which outputs a 0% to 100% score, and DISCERN, a 1 (unsatisfactory) to 5 (highly satisfactory) scoring system. Descriptive statistics were used to evaluate performance and compare chatbots amongst each other. Mean reading grade level (RGL) across all chatbots was 13.7. Calculated RGLs for ChatGPT, Copilot, Gemini and Meta were 14.2, 14.0, 12.5, 14.2, respectively. Mean DISCERN scores across the chatbots was 4.2. DISCERN scores for ChatGPT, Copilot, Gemini, and Meta were 4.2, 4.3, 4.2, and 3.9, respectively. Median PEMAT scores for understandability and actionability were 91.7% and 75%, respectively. Understandability and actionability scores for ChatGPT, Copilot, Gemini, and Meta were 100% and 75%, 91.7% and 75%, 90.9% and 75%, and 91.7% and 50%, respectively. AI chatbots produce high quality PEM with poor readability. We do not discourage using chatbots to create PEM but recommend cautioning patients about their readability concerns. AI chatbots are not an alternative to a healthcare provider. Furthermore, there is no consensus on which chatbots create the highest quality PEM. Future studies are needed to assess the effectiveness of AI chatbots in providing PEM to patients and how the capabilities of AI chatbots are changing over time.
- 11 April 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (15) , e42135
Top Cited PapersOpen AccessAssessing the quality and readability of patient education materials on chemotherapy cardiotoxicity from artificial intelligence chatbots: An observational cross-sectional study
Artificial intelligence (AI) and the introduction of Large Language Model (LLM) chatbots have become a common source of patient inquiry in healthcare. The quality and readability of AI-generated patient education materials (PEM) is the subject of many studies across multiple medical topics. Most demonstrate poor readability and acceptable quality. However, an area yet to be investigated is chemotherapy-induced cardiotoxicity. This study seeks to assess the quality and readability of chatbot created PEM relative to chemotherapy-induced cardiotoxicity. We conducted an observational cross-sectional study in August 2024 by asking 10 questions to 4 chatbots: ChatGPT, Microsoft Copilot (Copilot), Google Gemini (Gemini), and Meta AI (Meta). The generated material was assessed for readability using 7 tools: Flesch Reading Ease Score (FRES), Flesch-Kincaid Grade Level (FKGL), Gunning Fog Index (GFI), Coleman-Liau Index (CLI), Simple Measure of Gobbledygook (SMOG) Index, Automated Readability Index (ARI), and FORCAST Grade Level. Quality was assessed using modified versions of 2 validated tools: the Patient Education Materials Assessment Tool (PEMAT), which outputs a 0% to 100% score, and DISCERN, a 1 (unsatisfactory) to 5 (highly satisfactory) scoring system. Descriptive statistics were used to evaluate performance and compare chatbots amongst each other. Mean reading grade level (RGL) across all chatbots was 13.7. Calculated RGLs for ChatGPT, Copilot, Gemini and Meta were 14.2, 14.0, 12.5, 14.2, respectively. Mean DISCERN scores across the chatbots was 4.2. DISCERN scores for ChatGPT, Copilot, Gemini, and Meta were 4.2, 4.3, 4.2, and 3.9, respectively. Median PEMAT scores for understandability and actionability were 91.7% and 75%, respectively. Understandability and actionability scores for ChatGPT, Copilot, Gemini, and Meta were 100% and 75%, 91.7% and 75%, 90.9% and 75%, and 91.7% and 50%, respectively. AI chatbots produce high quality PEM with poor readability. We do not discourage using chatbots to create PEM but recommend cautioning patients about their readability concerns. AI chatbots are not an alternative to a healthcare provider. Furthermore, there is no consensus on which chatbots create the highest quality PEM. Future studies are needed to assess the effectiveness of AI chatbots in providing PEM to patients and how the capabilities of AI chatbots are changing over time.
- Open Access
Magnesium and Potassium Supplementation for Systolic Blood Pressure Reduction in the General Normotensive Population: A Systematic Review and Subgroup Meta-Analysis for Optimal Dosage and Treatment Length
Background/Objectives: Studies have shown that consistent reductions of 2 mm Hg in systolic blood pressure (SBP) for the general normotensive population can result in significant decreases in mortality from heart disease and stroke. The purpose of this meta-analysis was to determine the optimal dose and duration of treatment for magnesium and potassium supplementation, having previously discovered that both reduce SBP by −2.79 and −2.10 mm Hg, respectively. Methods: Placebo-controlled, randomized clinical trials examining the effects of magnesium and potassium supplementation on SBP were identified. Pairwise meta-analyses with subgroups for dosage and treatment duration were run. Results: Magnesium at dosages of ≤360 mg/day and durations greater than 3 months reduced SBP by −3.03 and −4.31 mm Hg, respectively. Potassium at dosages of ≤60 mmol/day and durations greater than 1 month reduced SBP by −2.34 and −2.80 mm Hg, respectively. Conclusions: Both supplements demonstrated greater reductions in SBP for the general population at lower dosages and longer treatment durations. Future studies are needed to validate these findings and provide tailored recommendations. These studies could investigate varying dosages over long-term follow-up to provide robust data on optimal dosages and treatment durations, as our findings were limited due to reliance on previously published trials.
Open AccessMagnesium and Potassium Supplementation for Systolic Blood Pressure Reduction in the General Normotensive Population: A Systematic Review and Subgroup Meta-Analysis for Optimal Dosage and Treatment Length
Background/Objectives: Studies have shown that consistent reductions of 2 mm Hg in systolic blood pressure (SBP) for the general normotensive population can result in significant decreases in mortality from heart disease and stroke. The purpose of this meta-analysis was to determine the optimal dose and duration of treatment for magnesium and potassium supplementation, having previously discovered that both reduce SBP by −2.79 and −2.10 mm Hg, respectively. Methods: Placebo-controlled, randomized clinical trials examining the effects of magnesium and potassium supplementation on SBP were identified. Pairwise meta-analyses with subgroups for dosage and treatment duration were run. Results: Magnesium at dosages of ≤360 mg/day and durations greater than 3 months reduced SBP by −3.03 and −4.31 mm Hg, respectively. Potassium at dosages of ≤60 mmol/day and durations greater than 1 month reduced SBP by −2.34 and −2.80 mm Hg, respectively. Conclusions: Both supplements demonstrated greater reductions in SBP for the general population at lower dosages and longer treatment durations. Future studies are needed to validate these findings and provide tailored recommendations. These studies could investigate varying dosages over long-term follow-up to provide robust data on optimal dosages and treatment durations, as our findings were limited due to reliance on previously published trials.